Shares

16 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2022

Nov 14, 2022

SELL
$8.63 - $15.52 $147,357 - $265,004
-17,075 Reduced 11.79%
127,706 $1.13 Million
Q2 2022

Aug 15, 2022

BUY
$8.59 - $20.77 $31,130 - $75,270
3,624 Added 2.57%
144,781 $1.83 Million
Q1 2022

May 11, 2022

BUY
$15.52 - $35.65 $40,398 - $92,796
2,603 Added 1.88%
141,157 $2.67 Million
Q4 2021

Feb 11, 2022

SELL
$28.89 - $35.33 $5,691 - $6,960
-197 Reduced 0.14%
138,554 $4.86 Million
Q3 2021

Nov 12, 2021

BUY
$35.66 - $42.94 $175,839 - $211,737
4,931 Added 3.68%
138,751 $5.08 Million
Q2 2021

Aug 11, 2021

SELL
$23.7 - $39.27 $285,182 - $472,535
-12,033 Reduced 8.25%
133,820 $5.26 Million
Q1 2021

May 13, 2021

BUY
$27.01 - $36.8 $520,401 - $709,025
19,267 Added 15.22%
145,853 $4.12 Million
Q4 2020

Feb 09, 2021

BUY
$27.51 - $34.36 $89,104 - $111,292
3,239 Added 2.63%
126,586 $4.05 Million
Q3 2020

Nov 12, 2020

SELL
$25.8 - $34.61 $387 - $519
-15 Reduced 0.01%
123,347 $3.98 Million
Q2 2020

Aug 12, 2020

BUY
$17.65 - $28.05 $559,734 - $889,549
31,713 Added 34.6%
123,362 $3.4 Million
Q1 2020

May 06, 2020

BUY
$15.19 - $29.51 $22,952 - $44,589
1,511 Added 1.68%
91,649 $1.64 Million
Q4 2019

Feb 14, 2020

SELL
$17.17 - $25.95 $11,040 - $16,685
-643 Reduced 0.71%
90,138 $2.26 Million
Q3 2019

Nov 07, 2019

BUY
$17.84 - $22.69 $88,914 - $113,086
4,984 Added 5.81%
90,781 $1.62 Million
Q2 2019

Aug 12, 2019

BUY
$22.0 - $31.78 $247,896 - $358,097
11,268 Added 15.12%
85,797 $1.89 Million
Q1 2019

May 14, 2019

BUY
$21.27 - $30.58 $195,662 - $281,305
9,199 Added 14.08%
74,529 $2.28 Million
Q4 2018

Feb 11, 2019

BUY
$23.09 - $37.69 $1.51 Million - $2.46 Million
65,330 New
65,330 $1.51 Million

Others Institutions Holding HCM

About HUTCHMED (China) Ltd


  • Ticker HCM
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—Specialty & Generic
  • Shares Outstandng 172,955,008
  • Market Cap $2.47B
  • Description
  • HUTCHMED (China) Limited discovers, develops, and commercializes targeted therapeutics and immunotherapies for cancer and immunological diseases in HongKong and internationally. It operates in Oncology/Immunology and Other Ventures segments. The company develops Savolitinib, an inhibitor for non-small cell lung cancer (NSCLC), papillary and rena...
More about HCM
Track This Portfolio

Track Bank Of New York Mellon Corp Portfolio

Follow Bank Of New York Mellon Corp and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Bank Of New York Mellon Corp, based on Form 13F filings with the SEC.

News

Stay updated on Bank Of New York Mellon Corp with notifications on news.